Janssen-Cilag International, a subsidiary of Johnson & Johnson, has released positive data from Phase 3 trials for its multiple myeloma treatment Darzalex (daratumumab). The results showed improved minimal residual disease negativity rates and progression-free survival in patients with newly diagnosed multiple myeloma.
The CEPHEUS trial combination of Darzalex with bortezomib, lenalidomide, and dexamethasone demonstrated significant improvement in MRD negativity rates and overall sustained response. The AURIGA study also showed enhanced progression-free survival with the same regimen.
Darzalex’s effectiveness was particularly notable in older patients and those with certain genetic markers. Patients over 65 years old achieved higher MRD-negative conversion rates, while Black and white patients saw similar improvements.
In addition to Darzalex, Janssen-Cilag announced promising results for its other multiple myeloma treatment Tecvayli (teclistamab-cqyv). The AQUILA study delayed disease progression and extended overall survival in high-risk smouldering multiple myeloma patients.
Source: https://www.worldpharmaceuticals.net/news/daratumumab-sc-based-regimens-show-improved-mrd-negativity-and-pfs-in-phase-3-ndmm-trials